OTC Athlete’s Foot Drugs Scheduled For FDA Advisory Committee Review
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs advisory committees are scheduled to review OTCs used in treatment of interdigital tinea pedis at a May 6-7 meeting in Rockville, Md
You may also be interested in...
NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
FDA's Nonprescription and Dermatologic & Ophthalmic Drugs advisory committees will discuss clinical trial design and future development programs for drugs treating interdigital Tinea pedis during their May 6-7 meeting in Rockville, MD
Antifungal drug products
FDA amends final monograph for athlete's foot (tinea pedis) products to add the word "most" to product labeling. New labeling will read, "For effective treatment of most athlete's foot with daily use," or contain a similar statement, an Aug. 29 Federal Register notice says. Companies selling antifungal treatments with sales greater than $25,000 per year must comply by May 16, 2002, all other companies must comply by May 16, 2003; the proposed amendment to the 1993 monograph was issued in July 1999. CHPA commented in October that the change was unsupported by scientific evidence and would not "meet an important consumer need" (1"The Tan Sheet" Nov. 1, 1999, p. 6)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC